Noble Capital Markets Initiates Coverage On Unicycive Therapeutics with Outperform Rating, Announces Price Target of $6
Portfolio Pulse from Benzinga Newsdesk
Noble Capital Markets has initiated coverage on Unicycive Therapeutics (UNCY) with an Outperform rating and set a price target of $6.

February 14, 2024 | 5:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Noble Capital Markets initiated coverage on Unicycive Therapeutics with an Outperform rating and a price target of $6.
The initiation of coverage by Noble Capital Markets with an Outperform rating and a price target significantly above the current trading price is likely to generate positive sentiment among investors, potentially driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100